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Abstract
Background: An aqueous extract of multi-hypoglycemic herbs of Panax ginseng C.A.Meyer, Pueraria lobata,
Dioscorea batatas Decaisne, Rehmannia glutinosa, Amomum cadamomum Linné, Poncirus fructus and Evodia
officinalis was investigated for its anti-diabetic effects in cell and animal models.
Methods: Activities of PPARg agonist, anti-inflammation, AMPK activator and anti-ER stress were measured in cell
models and in db/db mice (a genetic animal model for type 2 diabetes).
Results: While the extract stimulated PPARg-dependent luciferase activity and activated AMPK in C2C12 cells, it
inhibited TNF-a-stimulated IKKb/NFkB signaling and attenuated ER stress in HepG2 cells. The db/db mice treated
with the extract showed reduced fasting blood glucose and HbA1c levels, improved postprandial glucose levels,
enhanced insulin sensitivity and significantly decreased plasma free fatty acid, triglyceride and total cholesterol.
Conclusion: The aqueous extract of these seven hypoglycemic herbs demonstrated many therapeutic effects for
the treatment of type 2 diabetes in cell and animal models.
Background
Caused by complex interactions of multiple factors, dia-
betes mellitus type 2 (type 2 diabetes) is characterized
by decreased secretion of insulin by the pancreas and
resistance to the action of insulin in various tissues (eg
muscle, liver, adipose), leading to impaired glucose
uptake [1]. Management of type 2 diabetes usually
begins with change of diet and exercise [2] and most
patients ultimately require pharmacotherapy, such as
oral anti-diabetic drug (OAD) [1]. OADs include sulfo-
nylurea, non-sulfonylurea secretagogues, biguanides (eg
metformin), thiazolidinediones (eg TZD or glitazone)
and glucosidase inhibitors and glucagon-like peptide-1
(GLP-1) inhibitor. All OADs, however, have adverse
effects, eg weight gain with sulfonylurea, non-sulfony-
lurea secretagogues or TZD, edema and anemia with
TZD [1].
A variety of medicinal herbal products including herbs
used in Chinese medicine have beneficial effects on dia-
betes [3] and used as non-prescription treatment for
diabetes [4]; many of these herbs have been formulated
into multi-herbal preparation for enhanced effects [5].
While traditional formulae are often prescribed, their
efficacy has yet to be investigated; recently, anti-diabetic
multi-herbal formulae were studied and reported [6,7].
The present study reports a new anti-diabetic formula
consisting of seven herbs, namely hypoglycaemic cadi-
dates including Panax ginseng C.A.Meyer, Pueraria
lobata, Dioscorea batatas Decaisne, Rehmannia gluti-
nosa [8], Amomum cadamomum Linné [9], Poncirus
fructus [10] and Evodia officinalis [11] which are avail-
able in South Korea. This formula’s anti-diabetic mole-
cular mechanisms and anti-hyperglycemic effects are




The dried herbs of Panax ginseng C.A. Meyer (Aralia
family), Pueraria lobata (Pea family), Dioscorea batatas
DECAISNE (Dioscoreaceae), Rehmannia glutinosa (Phry-
maceae), Amomum cadamomum Linné (Zingiberaceae),
Poncirus fructus(Rhamnaceae)) and Evodia officinalis
DODE(Rutaceae) were purchased from Kwangmyung-
dang Natural Pharmaceutical (Korea) and identified
morphologically, histologically and authenticated by Pro-
fessor Su-In Cho (School of Korean Medicine, Pusan
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National University, Korea) according to standard proto-
col in National Standard of Traditional Medicinal Mate-
rials of The Korean Pharmacopeia [12]. Voucher
specimens of all seven species were deposited in Pusan
National University, Korea.
Powders of the herbs were mixed in equal amount
(200 g each) and extracted in hot-water. The extract
was freeze dried to powder and melt by dimethylsulfox-
ide (DMSO) when used. Macelignan, an active com-
pound of Myristica fragrans Houtt (Myristicaceae), was
prepared for positive control [13].
Cell lines
Cell lines of human embryonic kidney (HEK) 293 (CRL-
1573), 3T3-L1 pre-adipocytes (CL-173), HepG2 hepato-
cytes (HB-8065) and C2C12 skeletal myoblast cells
(CRL-1772) were obtained from the American Type
Culture Collection (ATCC, USA). HEK293 and HepG2
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing glucose (Invitrogen, USA) supple-
mented with 10% (v/v) fetal bovine serum (Gibco BRL,
USA). The 3T3-L1 pre-adipocytes were differentiated as
described previously [14]. C2C12 skeletal myoblast cells
were grown in DMEM supplemented with 2% horse
serum to induce differentiation into myotubes.
Reporter assays
The PPAR ligand-binding activity was measured with a
GAL4/PPAR chimera assay and PPRE-tk-Luc reporter
assay as described previously [15]. HEK293 cells were
transfected with pFA-PPARg and pFR-Luc (UAS-Gal4-
luciferase) and treated with the extract, rosiglitazone
(Alexis Biochemicals, USA) or macelignan at doses ran-
ging from 2 to 10 μmol/L for 24 hours. For PPRE-tk-
Luc reporter assay, HepG2 (2 × 105 cells/well) were
transfected with PPRE-tk-Luc and incubated with the
extract, rosiglitazone or macelignan for 24 hours. The
luciferase activities were then determined with a lucifer-
ase assay system kit (Promega, USA).
To determine the anti-inflammatory activities and
anti-endoplasmic recticulum (ER) stress, we transfected
HepG2 cells (2 × 105 cells/well) with NFkB-Luc reporter
or ERSE-Luc reporter using a Cignal™ Reporter Assay
kit (SABiosciences, USA). The cells were then incubated
with the extract, rosiglitazone or macelignan for 24
hours. The luciferase activities were determined with a
Dual-Glo Luciferase assay system kit (Promega, USA).
Real-time RT-PCR
We performed Real-time RT-PCR to determine the
expression of adipose fatty acid-binding protein (aP2),
acyl-CoA synthetase (ACS) and carnitine palmitoyltrans-
ferase-1 (CPT-1). The total RNA was extracted with
TRIzol reagent (Invitrogen, USA) and subjected to
reverse transcription with M-MLV Reverse Transcrip-
tase (Promega, USA). The total RNA was then amplified
(with gene-specific primers) and quantified with a fluor-
escence thermocycler (iQ™5, Multicolor Real-Time
PCR System, Bio-Rad, USA).
Western blot analysis
Total proteins were extracted with PRO-PREP reagent
(iNtRON Biotechnology, Korea) and immuno-blotted
with the antibodies of p-AMPK, IkBa, GRP78 or p-elf2a
(Santa Cruz Biotechnology, USA) [15]. The immune
complexes were identified with an enhanced chemilumi-
nescence detection system (Amersham Biosciences, Swe-
den) according to the manufacturer’s instructions and in
conjunction with a Fluorochem gel image analyzer (MF-
Chem:BIS 3.2, Alpha Innotech, USA).
Animal study
Twenty-eight (28) male C57BL/KsJ-db/db mice aged 8
weeks were purchased from Jackson Laboratory (USA)
and individually housed in polycarbonate cages under a
12-hour light-dark cycle at 21-23°C and 40-60% humid-
ity. After a 2-week adaptation period, the body weight
and fasting blood glucose level of the 10-week-old mice
were measured. Then, the mice were equally divided
into four groups (n = 7): (1) diabetic control, (2) rosigli-
tazone, (3) macelignan and (4) treatment (with the
extract). All groups were fed a standard AIN-76 semi-
synthetic diet (American Institute of Nutrition) and
three experimental groups (rosigltiazone, macelignan
and treatment) were orally administered with rosiglita-
zone (10 mg/kg body weight), macelignan (15 mg/kg
body weight) or the extract (150 mg/kg body weight) for
three weeks. After starved for 12 hours, the mice were
anesthetized with ether and their blood samples were
collected from the inferior vena cava for the measure-
ment of the blood and plasma biomarkers such as
HbA1c and insulin. All animal handlings during the
experiments were in accordance with the Pusan
National University guidelines for the care and use of
laboratory animals.
Fasting blood glucose, blood HbA1c and plasma
biomarker analyses
During the experiments, the fasting blood glucose con-
centration was monitored by a Glucometer (GlucoDr,
Allmedicus, Korea) with venous blood drawn from the
mouse tail vein after a 12-hour fast. Moreover, the
blood glycosylated hemoglobin (HbA1c) collected from
sacrificed mice was measured with a MicroMat™ II
Hemoglobin A1c Test (Bio-Rad Laboratories, USA). All
blood samples obtained were centrifuged at 1000 × g for
15 min at 4°C for biochemical analysis. The plasma
insulin, glucagon and C-peptide levels were measured
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with the enzyme-linked immunosorbent assay (ELISA)
kits (ALPCO Diagnostics, USA).
Furthermore, the plasma lipids such as total choles-
terol and triglyceride were determined with commercial
kits (Sigma-Aldrich, USA) while the plasma free fatty
acid (FFA) concentration was determined with an ACS
(acyl-CoA synthetase)-ACOD(ascorbate oxidase) method
(Wako Pure Chemical Industries, Japan).
Intraperitoneal glucose tolerance test (IPGTT) and
intraperitoneal insulin tolerance test (IPITT)
On the third week of treatment, an intraperitoneal glu-
cose and insulin tolerance test (IPGTT and IPITT) were
performed on all db/db mice after a 12-hour overnight
fast. To determine the glucose and insulin tolerance, we
injected the mice intraperitoneally with glucose (0.5 g/
kg body weight) or insulin (2 unit/kg body weight). The
glucose concentrations of blood drawn from the tail
vein were determined immediately upon collection at
30, 60 and 120 min after glucose injection or at 30, 60
and 120 min after insulin injection.
Statistical analysis
All statistical tests were two-sided, and the level of sig-
nificance was set at 0.05. All data are presented as mean
± standard deviation (SD) for all groups. Statistical ana-
lyses were performed with the SPSS, version 18
(SPSSInc., Chicago, IL, USA). One-way ANOVA(analysis
of variance) with post-hoc test by Duncan’s multiple-
range test was used to examine differences among
groups. The data were analyzed by Student’s t-test for
two group comparison.
Results
Effect on PPARg agonist
To determine if the extract was a PPARg agonist, we
searched the cell-based GAL4/PPAR chimera transacti-
vation in Hek293 cells. As shown in Figure 1A, the
Figure 1 Extract functions as a PPARg agonist. (A) Extract increased the ligand-binding activity of PPARg. HEK293 cells were transfected with
pFA-PPARg and pFR-Luc (UAS-Gal4-luciferase) and then treated with extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours.
(B) Extract induced transcriptional activity of PPARg. Differentiated 3T3-L1 adipocytes were transfected with 3 × PPREs-tk-Luc and treated with
extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours. (C) Extract induced adipogenesis. Oil red O staining was measured
after differentiation of 3T3-L1 cells in medium containing 0.1% DMSO (control), extract (5 μg/ml), rosiglitazone (1 μM), or macelignan (10 μM) for
seven days. (D) Extract increased PPARg target gene (aP2) expression in 3T3-L1 adipocytes. Differentiated 3T3-L1 cells were treated with extract (5
μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours. Expression of mRNAs was estimated using quantitative real-time RT-PCR, and
the results were expressed as mRNA levels relative to 0.1% DMSO (control). Data represent are shown as mean ± SD of three independent
experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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extract increased the PPARg-dependent luciferase activity
(P = 0.035 vs non-treatment) similar to that of rosiglita-
zone (P = 0.001 vs non-treatment), a well-known PPARg
agonist, and macelignan (P = 0.005 vs non-treatment), a
PPARa/g dual agonist used as positive control through-
out the experiments. To further explore the PPARg ago-
nist potential of the extract, transient transfections were
performed in differentiated 3T3-L1 adipocytes with the
tk-luciferase vector containing PPAR-responsive ele-
ments (PPREs) and then treated with the extract. The
treatment stimulated PPRE-dependent luciferase activ-
ities in transfected cells (P = 0.005 vs non-treatment)
(Figure 1B). To provide biological evidence that the
extract is a PPARg ligand, we investigated adipocyte dif-
ferentiation and expression of the adipocyte marker gene
in 3T3-L1 cells treated with the extract. The treatment
led to a significant increase in the formation of lipid dro-
plets in similar to rosiglitazone and macelignan (Figure
1C). Moreover, the extract increased the expression of
adipose fatty acid-binding protein (aP2) (P = 0.042 vs
non-treatment) (Figure 1D). Taken together, these results
demonstrated that the extract was a PPARg agonist.
Effect on AMPK activation
To determine if the extract mediated the AMP-activated
protein kinase (AMPK) activation, we measured the
AMPK phosphorylation and expression of fatty acid oxi-
dation genes in C2C12 cells incubated with the extract.
As with the AMPK activator, aminoimidazole-4-carbox-
amide-1-b-d-ribofuranoside (AICAR) (P = 0.001 vs non-
treatment), the treatment activated AMPK in C2C12
cells (P = 0.007 vs non-treatment), similar to when sam-
ples were treated with macelignan (P = 0.042 vs non-
treatment) (Figure 2A). Consistent with the results of
AMPK phosphorylation, the treatment increased the
expression of acyl-CoA synthetase (ACS) (P = 0.048 vs
non-treatment) and carnitine palmitoyltransferase-1
(CPT-1) (P = 0.041 vs non-treatment) (Figure 2B), sug-
gest that the extract activated AMPK.
Effect on inflammatory processes
As inflammatory processes play potential roles in the
pathogenesis of insulin resistance, we investigated
whether the extract possessed anti-inflammatory effects,
including the inhibitory effects of the extract on IKKb/
NFkB signaling in HepG2 cells treated with TNF-a
using NFkB response element containing reporter.
While TNF-a treatment increased the NFkB-dependent
luciferase activity (P = 0.001 vs non-treatment), The
extract effectively prevented this increase (P = 0.034 vs
TNF-a treatment) (Figure 3A). Furthermore, the extract
increased the IkBa level reduced by TNF-a treatment,
Figure 2 Extract activates AMPK in C2C12 cells. (A) Extract increased AMPK phosphorylation. C2C12 cells were treated with aminoimidazole-
4-carboxamide-1-b-d-ribofuranoside (1 mmol/l), extract (5 μg/ml), or macelignan (10 μM) for 24 hours. Phosphorylated AMPK was examined by
Western blot analysis, (B) extract increased the mRNA expression of ACS, CPT-1. The expression was estimated using quantitative real-time RT-
PCR. Data represent are shown as mean ± SD of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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which was consistent with rosiglitazone and macelignan
(Figure 3B). These results indicated that the extract
exerted anti-inflammatory effects.
Effect on attenuation of ER stress
It has been recently suggested that ER stress plays a
central role in the development of insulin resistance and
diabetes by impairing insulin signaling through c-Jun
NH2-terminal kinase (JNK) activation [16]. Therefore,
we investigated whether the extract inhibited ER stress.
We first examined the inhibitory effects on the lucifer-
ase activity of ERSE response element containing repor-
ter in HepG2 cells treated with the ER stress inducer,
thapsigargin. While thapsigargin treatment increased the
ERSE-dependent luciferase activity (P = 0.001 vs non-
treatment), the extract effectively blocked the thapsigar-
gin-mediated stimulation (P = 0.039 vs thapsigargin
treatment) (Figure 4A). When ER stress indicators such
as GRP78 and p-elF2a were examined in thapsigargin-
treated HepG2 cells, Treatment by the extract
suppressed the increase of the indicators by thapsigargin
(P = 0.045 vs thapsigargin treatment) (Figure 4B). Taken
together, these results demonstrated that the extract
exerted protective effects against ER stress.
Effects on body weight change and fasting blood glucose
in db/db mice
To examine the in vivo anti-diabetic effects of the
extract on diabetes, we orally administered rosiglitazone
(10 mg/kg), macelignan (15 mg/kg) and the extract (150
mg/kg) to C57BL/KsJ-db/db mice every day for three
weeks and the extract’s effects were compared with rosi-
glitazone and macelignan. Treatment with the extract
did not have a significant effect on the body weights in
the db/db mice; however, mice treated with rosiglitazone
had final body weights significantly higher than those of
the others (P = 0.001 vs control) (Figure 5A). The base-
line (day 0) fasting blood glucose levels did not differ
between groups; however, at the end of the experiment,
the values of the extract-treated group were significantly
lower compared to the diabetic control group (P =
0.022 vs control) and so did the other groups treated
with rosiglitazone (P = 0.001 vs control) and macelignan
(P = 0.002 vs control). The blood glucose levels of the
extract-treated mice were significantly reduced by about
15% compared to the control (Figure 5B).
Effects on postprandial glucose and insulin sensitivity in
db/db mice
To assess glucose homeostasis and insulin sensitivity in
db/db mice treated with the extract, we performed glu-
cose tolerance and insulin tolerance tests before the end
of the experiment. As shown in Figure 6A, the extract
significantly reduced the blood glucose levels (P = 0.001
vs control) similar to rosiglitazone (P = 0.003 vs control)
and macelignan (P = 0.004 vs control) used as positive
controls compared with the diabetic control groups. The
insulin tolerance test also showed that reduction in
blood glucose levels in response to insulin was much
greater in mice treated with the extract than in
untreated db/db mice (P = 0.002 vs control) (Figure 6B).
These findings indicate that treatment with the extract
affected not only regulation of the postprandial glucose
level, but also enhanced the insulin sensitivity.
Effects on plasma lipids in db/db mice
Effects of the extract on plasma triglycerides and FFAs
levels and total cholesterol were investigated. Specifi-
cally, treatment with the extract significantly decreased
the plasma free fatty acid (P = 0.021 vs control), trigly-
ceride (P = 0.012 vs control) and total cholesterol (P =
0.003 vs control) concentrations of the diabetic control
db/db mice compared with untreated db/db mice when
the experiment ended (Table 1). As lipolysis and
Figure 3 Extract inhibits NFkB signaling in HepG2 cells. (A)
extract prevented the increase of TNF-a-stimulated luciferase
activity in TNF-a treated HepG2. HepG2 cells were transfected with
NFkB-Luc reporter and then treated with extract (5 μg/ml),
rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours in the
presence of TNF-a (10 ng/ml) (B) extract increased the IkB level.
HepG2 cells were preincubated with extract (5 μg/ml), rosiglitazone
(10 μM), or macelignan (10 μM) for 24 hours and then treated with
TNF-a (10 ng/ml) for one hour. IBa was measured by Western blot
analysis. Data represent are shown as mean ± SD of three
independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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circulating free fatty acids increase under insulin resis-
tance conditions, these results demonstrate that the
decrease in plasma lipids may contribute to the
improvement of severe diabetes, at least partially.
Effects on glycosylated hemoglobin level and plasma
biomarkers in db/db mice
Mice receiving the treatment with the extract showed a
significantly lower blood glycosylated hemoglobin level
compared to the diabetic control db/db mice (P = 0.002
vs control). Both the plasma insulin (P = 0.042 vs con-
trol) and C-peptide levels (P = 0.038 vs control) were
significantly higher in the extract-treated db/db mice
than in the diabetic control db/db mice; however, the
glucagon levels were significantly lower than those of
the diabetic control db/db mice (P = 0.018 vs control).
Therefore, treatment with the extract significantly
improved the ratio of insulin/glucagon (I/G) when com-
pared to the diabetic control db/db mice (Table 2).
Discussion
In this study, we tested a formulation of seven medicinal
herbs including Panax ginseng C.A.Meyer for the anti-
diabetic effects in cells and in vivo. We found that the
extract from the seven herbs functioned as PPARg ago-
nists and an AMPK activators, as well as inhibitors of
inflammation and ER stress. PPARg can improve insulin
sensitivity and glucose tolerance by regulating lipid sto-
rage, glucose homeostasis and adipokine regulation [17].
The TZD group, especially rosiglitazone and troglitazone,
are agonists of PPARg [18]. The extract significantly
increased the PPARg-dependent luciferase activity in
vitro and stimulated the formation of lipid droplets and
the expression of aP2 upon transient transfection of 3T3-
L1 cells. Rb1, the most abundant ginsenoside in ginseng
root, increases the expression of mRNA and protein of
PPARg and exerts anti-diabetic and insulin-sensitizing
activities [19]. 20(S)-protopanaxatriol (PPT), a ginseno-
side metabolite, increases PPARg-transactivation activity
Figure 4 Extract attenuates the induction of ER stress. (A) Extract prevented the increase of thapsigargin-stimulated luciferase activity in
thapsigargin-treated HepG2. HepG2 cells were transfected with ERSE-Luc reporter and then treated with extract (5 μg/ml), rosiglitazone (10 μM),
or macelignan (10 μM) for 24 hours in the presence of thapsigargin (10 ng/ml). (B) Extract increased the levels of GRP78 and peIF. HepG2 cells
were preincubated with extract (5 μg/ml), rosiglitazone (10 μM), or macelignan (10 μM) for 24 hours and then treated with thapsigargin (10 ng/
ml) for 24 hours. GRP78 p-eIF were measured by Western blot analysis. Data represent are shown as mean ± SD of three independent
experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
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with an activity similar to troglitazone, and up-regulates
the expression of PPARg target genes such as aP2, LPL
and PEPCK [15]. Therefore, the activity of PPARg against
may be due to Panax ginseng. Further studies are
required to confirm this speculation.
Activation of AMPK enhances insulin sensitivity
through increased glucose uptake and lipid oxidation in
skeletal muscle and inhibition of glucose and lipid
synthesis in the liver [20]. Metformin acts as an activa-
tor of AMPK in the liver and skeletal muscle [21]. The
present study demonstrated that the extract activated
AMPK in C2C12 and induced increased expression of
AMPK target genes. Ginsenoside Rh2 and Rg3, a red
ginseng rich constituent, activates AMPK significantly in
Figure 5 Extract beneficial effects on (A) body weight and (B) fasting blood glucose level in db/db mice after 3-week treatment. Values
shown are mean ± SD (n = 7). abcd Data not sharing a common letter are significantly different (P < 0.05) after one-way ANOVA and Duncan’s
multiple-range test. NS: non-significance.
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3T3-L1 adipocytes and to contribute to antiobesity
effects [22,23]. Further studies are required to character-
ize which herb activates AMPK.
Inflammatory cytokines and IKK attenuate insulin sig-
naling through serine phosphorylation of IRS-1 [24].
High doses of salicylates, which block the IKKb activity,
ameliorate hyperglycemia and insulin resistance in
diabetes and obesity [25]. Our results showed that the
extract effectively suppressed NFkB-dependent luciferase
activity in TNF-a-treated HepG2 cells and increased the
IkB level, suggesting that the extract blocked the activa-
tion of the NF-B pathways.
By activating c-Jun amino-terminal kinase (JNK),
which induces insulin resistance in liver and skeletal
Figure 6 Extract improved (A) postprandial glucose and (B) insulin sensitivity in db/db mice. After a 12-hourfast, male mice (12 weeks-old)
were intraperitoneally injected with glucose (0.5 g/kg body weight) and insulin (2 units/kg body weight). The blood glucose concentration was
then measured at the indicated times and was presented as a percentage of the glucose injection zero time. Values are mean ± SD (n = 7).abcd
Data not sharing a common letter are significantly different (P < 0.05) after one-way ANOVA and Duncan’s multiple-range test.
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muscle and inhibits beta cell function, ER stress induces
the development of type 2 diabetes [26]. Thus, agents
that alleviate ER stress may act as potent anti-diabetic
agents. Chemical or biological compounds such as
macelignan [27], chromium-phenylalanine [28], PBA
(phenyl butyric acid) [29] or TUDCA (tauroursodeoxy-
cholic acid) [30] or molecular chaperon have been
shown to inhibit ER stress and enhance insulin sensitiv-
ity, thereby normalizing hyperglycemia. The present
study found that the extract alleviated ER stress and effi-
ciently suppressed ERSE-dependent transactivation in
thapsigargin-treated HepG2 and expression of ER stress
marker proteins. In future studies, we will determine the
optimal combination ratio for this formulation and iso-
late its active fractions.
Conclusion
The aqueous extract of these seven hypoglycemic herbs
demonstrated anti-diabetic effects on type 2 diabetes.
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